NEW YORK, March 29, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that it is sponsoring psychedelic research at the Mount Sinai
Center for Psychedelic Psychotherapy and Trauma Research (the
"Center"). The Center examines the therapeutic potential of
psychedelic compounds for post-traumatic stress disorder (PTSD) and
other trauma-related symptoms.
Health care for post-traumatic stress disorder (PTSD) is
reaching a crisis point. Each year, over 8.6 million adults grapple
with PTSD, and nearly ten percent of Americans will experience PTSD
at some time in their lives. Combat veterans in particular, are at
an even greater risk, with an estimated 11-20 percent of veterans
who served in Iraq or Afghanistan having PTSD annually. Over half a
million veterans have sought treatment for PTSD in the last few
years, some having received treatment for decades. Currently,
no academic institution, other than the Center, is conducting
research involving the administration of psychedelics inside the VA
System.
The Center works to provide novel clinical therapies utilizing
MDMA, psilocybin, and other psychedelics through FDA-approved
research protocols. More specific to the Company's support,
the Center will be embarking on clinical trials with MDMA and
psilocybin. As part of these studies the Center will be
collecting blood samples and performing neuroimaging before and
after therapy to identify biomarkers that predict and correlate
with positive treatment outcome.
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers, and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of
Texas at Austin and Wake
Forest University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: info@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-sponsors-psychedelic-compound-research-to-treat-ptsd-301257485.html
SOURCE AIkido Pharma Inc.